Alnylam Pharmaceuticals
ALNY
#638
Rank
ยฃ22.87 B
Marketcap
ยฃ176.73
Share price
1.76%
Change (1 day)
51.46%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -ยฃ0.19 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are ยฃ2.24 Billion. , an increase over its 2023 earnings that were of -ยฃ0.24 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 -ยฃ0.18 Billion-24.59%
2023 -ยฃ0.24 Billion-67.84%
2022 -ยฃ0.74 Billion36.93%
2021 -ยฃ0.54 Billion-8.04%
2020 -ยฃ0.59 Billion-15.66%
2019 -ยฃ0.69 Billion12.23%
2018 -ยฃ0.62 Billion62.91%
2017 -ยฃ0.38 Billion17.78%
2016 -ยฃ0.32 Billion43.44%
2015 -ยฃ0.23 Billion60.69%
2014 -ยฃ0.14 Billion98.2%
2013 -ยฃ70.03 Million
2011 -ยฃ41.31 Million27.48%
2010 -ยฃ32.4 Million-10.92%
2009 -ยฃ36.38 Million95.77%
2008 -ยฃ18.58 Million
2006 -ยฃ29.77 Million-9.13%
2005 -ยฃ32.76 Million34.74%
2004 -ยฃ24.31 Million36.79%
2003 -ยฃ17.78 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-ยฃ0.46 Billion 154.87%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ3.60 B-2,129.54%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ0.19 B-210.72%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ7.81 Million-95.60%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ34.81 Million-80.38%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ10.27 B-5,891.51%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
ยฃ5.98 B-3,472.17%๐Ÿ‡ซ๐Ÿ‡ท France
-ยฃ0.22 Billion 19.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel